Latigo Biotherapeutics, Inc. (LTGO)
Data as of , from SEC Form 4 filings.
Net insider buying (90d)Watch LTGO
See up to 3 months of LTGO. The 7-day demo opens the 1M and 3M ranges and puts LTGO on your watchlist.
Start 7-day demoLatest LTGO insider trades
About Latigo Biotherapeutics, Inc. (LTGO)
The SEC lists Latigo Biotherapeutics, Inc. under CIK 0002056611, in pharmaceutical preparations. We track it alongside the rest of the Health Care sector. Its offering priced on 7 August 2026 and it trades on NASDAQ.
LTGO Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market purchase | 2 | 280,000 | $5.04M |
| Grant or award | 1 | 105,542 | |
| Other acquisition / disposition | 66 | 102,944,012 |
Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.
LTGO insider transactions (Form 4)
697 Form 4 filings on record, the earliest from Aug 11, 2026, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 5AM Ventures VI, L.P. - 10% Owner | Other | Common Stock | 4,975,543 | - footnote F1 | - | |
| 5AM Ventures VI, L.P. - 10% Owner | Other | Common Stock | 2,350,419 | - footnote F1 | - | |
| 5AM Ventures VI, L.P. - 10% Owner | Other | Series A Preferred Stock | 3,152,305 | $0.00 | - | |
| 5AM Ventures VI, L.P. - 10% Owner | Other | Series A-2 Preferred Stock | 1,823,238 | $0.00 | - | |
| 5AM Ventures VI, L.P. - 10% Owner | Other | Series A-2 Preferred Stock | 866,018 | $0.00 | - | |
| 5AM Ventures VI, L.P. - 10% Owner | Other | Series B Preferred Stock | 1,484,401 | $0.00 | - | |
| ||||||
| Sanofi - 10% Owner | Other | Common Stock | 494,800 | - footnote F1 | - | |
| Sanofi - 10% Owner | Other | Common Stock | 177,978 | - footnote F2 | - | |
| Sanofi - 10% Owner | Other | Series B Preferred Stock | 494,800 | - footnote F1 | - | |
| Sanofi - 10% Owner | Other | Convertible Promissory Note | 177,978 | - footnote F2 | - | |
| ||||||
| Westlake BioPartners Fund I, L.P. - 10% Owner | Other | Common Stock | 938,979 | - footnote F1 | - | |
| Westlake BioPartners Fund I, L.P. - 10% Owner | Other | Common Stock | 3,547,842 | - footnote F1 | - | |
| Westlake BioPartners Fund I, L.P. - 10% Owner | Other | Common Stock | 1,027,635 | - footnote F1 | - | |
| Westlake BioPartners Fund I, L.P. - 10% Owner | Other | Common Stock | 3,464,072 | - footnote F1 | - | |
| Westlake BioPartners Fund I, L.P. - 10% Owner | Other | Common Stock | 1,484,401 | - footnote F1 | - | |
| Westlake BioPartners Fund I, L.P. - 10% Owner | Other | Common Stock | 165,519 | - footnote F4 | - | |
| Westlake BioPartners Fund I, L.P. - 10% Owner | Other | Common Stock | 2,066,857 | - footnote F1 | - | |
| Westlake BioPartners Fund I, L.P. - 10% Owner | Other | Series Seed Convertible Preferred Stock | 938,979 | - footnote F1 | - | |
| Westlake BioPartners Fund I, L.P. - 10% Owner | Other | Series A Convertible Preferred Stock | 3,547,842 | - footnote F1 | - | |
| Westlake BioPartners Fund I, L.P. - 10% Owner | Other | Series A-2 Convertible Preferred Stock | 1,027,635 | - footnote F1 | - | |
| Westlake BioPartners Fund I, L.P. - 10% Owner | Other | Series A-2 Convertible Preferred Stock | 3,464,072 | - footnote F1 | - | |
| Westlake BioPartners Fund I, L.P. - 10% Owner | Other | Series B Convertible Preferred Stock | 1,484,401 | - footnote F1 | - | |
| Westlake BioPartners Fund I, L.P. - 10% Owner | Other | Series A-2 Convertible Preferred Stock | 2,066,857 | - footnote F1 | - | |
| Westlake BioPartners Fund I, L.P. - 10% Owner | Other | Convertible Promissory Note | 165,519 | - footnote F4 | - | |
| ||||||
| Foresite Capital Management V, LLC - 10% Owner | Other | Common Stock | 3,117,664 | $0.00 | - | |
| Foresite Capital Management V, LLC - 10% Owner | Other | Common Stock | 445,320 | $0.00 | - | |
| Foresite Capital Management V, LLC - 10% Owner | Other | Common Stock | 1,125,823 | $0.00 | - | |
| Foresite Capital Management V, LLC - 10% Owner | Other | Common Stock | 742,201 | $0.00 | - | |
| Foresite Capital Management V, LLC - 10% Owner | Open-market purchase | Common Stock | 140,000 | $18.00 | $2.52M | |
| Foresite Capital Management V, LLC - 10% Owner | Other | Common Stock | 195,776 | - footnote F5 | - | |
| Foresite Capital Management V, LLC - 10% Owner | Other | Common Stock | 3,117,664 | $0.00 | - | |
| Foresite Capital Management V, LLC - 10% Owner | Other | Common Stock | 296,880 | $0.00 | - | |
| Foresite Capital Management V, LLC - 10% Owner | Other | Series A-2 Convertible Preferred Stock | 3,117,664 | $0.00 | - | |
| Foresite Capital Management V, LLC - 10% Owner | Other | Series B Convertible Preferred Stock | 445,320 | $0.00 | - | |
| Foresite Capital Management V, LLC - 10% Owner | Other | Series A-2 Convertible Preferred Stock | 1,125,823 | $0.00 | - | |
| Foresite Capital Management V, LLC - 10% Owner | Other | Series B Convertible Preferred Stock | 742,201 | $0.00 | - | |
| Foresite Capital Management V, LLC - 10% Owner | Other | Series A-2 Convertible Preferred Stock | 3,117,664 | $0.00 | - | |
| Foresite Capital Management V, LLC - 10% Owner | Other | Series B Convertible Preferred Stock | 296,880 | $0.00 | - | |
| Foresite Capital Management V, LLC - 10% Owner | Other | Convertible Promissory Note | 195,776 | - footnote F5 | - | |
| ||||||
| Todd N. Smith - Director | Grant or award | Director Stock Option (right to buy) | 105,542 | $0.00 | - | |
| James B. Tananbaum - Director | Other | Common Stock | 3,117,664 | - footnote F1 | - | |
| James B. Tananbaum - Director | Other | Common Stock | 445,320 | - footnote F1 | - | |
| James B. Tananbaum - Director | Other | Common Stock | 1,125,823 | - footnote F1 | - | |
| James B. Tananbaum - Director | Other | Common Stock | 742,201 | - footnote F1 | - | |
| James B. Tananbaum - Director | Open-market purchase | Common Stock | 140,000 | $18.00 | $2.52M | |
| James B. Tananbaum - Director | Other | Common Stock | 195,776 | - footnote F4 | - | |
| James B. Tananbaum - Director | Other | Common Stock | 3,117,664 | - footnote F1 | - | |
| James B. Tananbaum - Director | Other | Common Stock | 296,880 | - footnote F1 | - | |
| James B. Tananbaum - Director | Other | Series A-2 Convertible Stock | 3,117,664 | - footnote F1 | - | |
| James B. Tananbaum - Director | Other | Series B Convertible Preferred Stock | 445,320 | - footnote F1 | - | |
| James B. Tananbaum - Director | Other | Series A-2 Convertible Preferred Stock | 1,125,823 | - footnote F1 | - | |
| James B. Tananbaum - Director | Other | Series B Convertible Preferred Stock | 742,201 | - footnote F1 | - | |
| James B. Tananbaum - Director | Other | Series A-2 Convertible Preferred Stock | 3,117,664 | - footnote F1 | - | |
| James B. Tananbaum - Director | Other | Series B Convertible Preferred Stock | 296,880 | - footnote F1 | - | |
| James B. Tananbaum - Director | Other | Convertible Promissory Note | 195,776 | - footnote F4 | - | |
| ||||||
| Beth C. Seidenberg - Director | Other | Common Stock | 938,979 | - footnote F1 | - | |
| Beth C. Seidenberg - Director | Other | Common Stock | 3,547,842 | - footnote F1 | - | |
| Beth C. Seidenberg - Director | Other | Common Stock | 1,027,635 | - footnote F1 | - | |
| Beth C. Seidenberg - Director | Other | Common Stock | 3,464,072 | - footnote F1 | - | |
| Beth C. Seidenberg - Director | Other | Common Stock | 1,484,401 | - footnote F1 | - | |
| Beth C. Seidenberg - Director | Other | Common Stock | 165,519 | - footnote F4 | - | |
| Beth C. Seidenberg - Director | Other | Common Stock | 2,066,857 | - footnote F1 | - | |
| Beth C. Seidenberg - Director | Other | Series Seed Convertible Stock | 938,979 | - footnote F1 | - | |
| Beth C. Seidenberg - Director | Other | Series A Convertible Preferred Stock | 3,547,842 | - footnote F1 | - | |
| Beth C. Seidenberg - Director | Other | Series A-2 Convertible Preferred Stock | 1,027,635 | - footnote F1 | - | |
| Beth C. Seidenberg - Director | Other | Series A-2 Convertible Preferred Stock | 3,464,072 | - footnote F1 | - | |
| Beth C. Seidenberg - Director | Other | Series B Convertible Preferred Stock | 1,484,401 | - footnote F1 | - | |
| Beth C. Seidenberg - Director | Other | Series A-2 Convertible Preferred Stock | 2,066,857 | - footnote F1 | - | |
| Beth C. Seidenberg - Director | Other | Convertible Promissory Note | 165,519 | - footnote F4 | - | |
| ||||||
Item 2.02, 9.01
Item 5.03, 8.01, 9.01
LTGO insider trading FAQ
What is the latest insider trade for LTGO?
Latigo Biotherapeutics, Inc. (LTGO) had 7 insider filings in the last 90 days, with the most recent on 2026-08-12. The full record for LTGO runs to 7 Form 4 filings, the earliest from 2026-08-11. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying LTGO stock?
2 insider purchases of LTGO were filed in the last 90 days, totaling $5.04M.
How many insiders are selling LTGO stock?
No insider sales of LTGO were filed in the last 90 days.
Where can I see LTGO SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects LTGO Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
7The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - 5AM Ventures VI, L.P. view on EDGAR
- - Sanofi view on EDGAR
- - Westlake BioPartners Fund I, L.P. view on EDGAR
- - Foresite Capital Management V, LLC view on EDGAR
- - Todd N. Smith view on EDGAR
- - James B. Tananbaum view on EDGAR
- - Beth C. Seidenberg view on EDGAR
Related companies with recent insider activity
Learn more
- How to read insider buying signals
- What an open-market purchase by an insider can and cannot tell you.
- Insider activity in Health Care
- Where LTGO's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow LTGO with a 7-day demo
- LTGO on your watchlist
- Every LTGO Form 4 filing on record
- Up to 3 months of LTGO price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
Start 7-day demoCard required. Your card is never charged for the demo.
